A Luxury Getaway in the Puteri Harbour Marina FrontISKANDAR PUTERI, Malaysia, April 09, 2026 (GLOBE NEWSWIRE) — Far East Consortium International Limited’s (“FEC”, Stock code: 35.HK) subsidiary Dorsett Hospitality International (“DHI”) is excited to announce the opening of Dao by Dorsett Puteri Cove on Friday 15 May 2026, its first Dao by Dorsett hotel in Malaysia. Guided by Dao by Dorsett’s core philosophy to “Live Your Way, Anywhere”, the hotel boasts a modern approach to upscale stays in Iskandar Puteri’s waterfront. Thoughtful Spaces for Balance and Comfort Rising 32 storeys above the marina, Dao by Dorsett Puteri Cove features 213 rooms across four categories: Studio, One Bedroom, Two Bedroom and Two Bedroom Plus Facility. Each suite is designed for independent living, featuring a fully equipped kitchenette, laundry facilities...

SAINT-BRUNO-DE-MONTARVILLE, Quebec, April 08, 2026 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”), announced today the conclusion of its sale and investment solicitation process (“SISP”) conducted under the supervision of the Superior Court of Québec (Commercial Division) (the “Court”) and Raymond Chabot Inc., as Court-appointed monitor of the Company (“Monitor”) in connection with the restructuring proceedings (the “CCAA Proceedings”) of the Company and certain of its subsidiaries, Transport Paul-Émile Dubé Ltée, Le Groupe Resto-Achats Inc. and Norref Fisheries Quebec Inc., instituted on January 8, 2026, under the Companies’ Creditors Arrangement Act (Canada). Following the issuance on March 31, 2026 by the Court of an approval and vesting order in respect of the sale of all outstanding shares of...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) — MegaWatt Lithium and Battery Metals Corp. (CSE:MEGA) (FSE: WR20) (OTCQB: WALRF) (the “Company“, or “MegaWatt”) announces that, it will enter into debt settlement agreements pursuant to which the Company will issue 3,067,000 common shares in the capital of the Company (the “Shares”) at a deemed price of $0.185 per Share to certain creditors of the Company (the “Creditors”) in settlement of an aggregate of $567,400 in debts owing to the Creditors for consulting, legal and administrative services provided to the Company (the “Shares for Debt Settlement“), including $99,700 owed to certain Directors and Officers of the Company. All the Shares issued in connection with...

CALGARY, Alberta, April 08, 2026 (GLOBE NEWSWIRE) — Calfrac Well Services Ltd. (“Calfrac” or the “Company”) (TSX: CFW) announces the appointment of Scarlett Crockatt as the Company’s new Chief Financial Officer effective April 9, 2026. Ms. Crockatt succeeds Mike Olinek, who is retiring from the Company. Tyler Dahlseide, Chief Executive Officer of Calfrac, said, “We are excited to announce Scarlett as Calfrac’s new CFO. As we enter our next phase, her expertise and fresh perspectives will strengthen Calfrac’s leadership team and support the Company’s focus on delivering value for all stakeholders.” Ms. Crockatt joins Calfrac as an accomplished finance executive with over 15 years of experience in capital markets, strategic finance and governance, including senior leadership roles at Roynat Capital,...

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) — Paloma Acquisition Corp I (Nasdaq: PALOU) (the “Company”) today announced that, commencing on April 13, 2026, holders of the units (the “Units”) sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares (the “Ordinary Shares”) and warrants (the “Warrants”) included in the Units. The Ordinary Shares and Warrants received from the separated Units will trade on the Nasdaq Global Market (“Nasdaq”) under the symbols “PALO” and “PALOW”, respectively. Units that are not separated will continue to trade on Nasdaq under the symbol “PALOU”. Holders of Units will need to have their brokers contact Efficiency INC., the Company’s transfer agent, in order to separate the Units into Ordinary Shares and Warrants. The Company was formed for the purpose...

Quarterly Production of 45,776 oz AuEq1 Closing cash and bullion $362 million – $130 million increase from DecemberQuarterly gold production of 45,776 AuEq1 oz, comprised of:Mine Group Q3(1 Jan – 31 Mar 2026) Group YTD2(1 Jul – 31 March 2026)  ProductionTomingley 21,652 Au oz 62,076 Au ozCosterfield 10,584 Au oz377 Sb t11,691 AuEq oz 29,986 Au oz842 Sb t32,869 AuEq ozBjörkdal 12,433 Au oz 30,901 Au ozConsolidated 44,669 Au oz377 Sb t45,776 AuEq oz 122,963 Au oz842 Sb t125,846 AuEq oz  SalesConsolidated 42,550 Au oz280 Sb t43,373 AuEq oz 119,596 Au oz829 Sb t122,416 AuEq ozCash, bullion and listed investment balance of $374 million.Increase of $128 million from the previous quarter. Alkane has cash & bullion of $362 million, and pro forma liquidity of $472 million when including an undrawn $110...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California. Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”) will be presented. The payload of HMPL-A580 potently inhibited PI3K and PIKK family kinases, with IC50 ranging around 1 to 10 nM. Eurofins profiling across 418 kinases revealed the payload has excellent selectivity. By conjugating this potent payload with an anti-EGFR antibody via a cleavable linker, the ATTC compound HMPL-A580...

MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning:Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years’ experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ: COO), a medical technology company, and also served as an independent director for Medidata from 2018-2019 until its successful merger with Dassault Systèmes. Dr. Rivas spent over 25 years in healthcare developing and commercializing...